This relative heterogeneity of ovarian cancer beyondBRCA1 and BRCA2 makes it ideally suited to either paneltesting or exome testing, whereby comprehensive testing of multiple genes inparallel is performed. The gene discussed is BRCA2; the disease is ovarian cancer.